First Nasal Vaccine Developed by Bharat Biotech

Bharat Biotech's intranasal vaccine is the first nasal vaccine that has received the regulatory approval for Phase 2 trials.
BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.
BBIL has in-licensed technology from Washington University in St Louis, USA.
The development of the vaccine is supported by the Department of Biotechnology (DBT) and its PSU, Biotechnology Industry Research Assistance Council (BIRAC)
Mission COVID Suraksha was launched to reinforce and accelerate COVID-19 vaccine development efforts under Atmanirbhar 3.0.